DPRX
TIP
Re: DPRX
Ik heb ze ook nog. Hoop op verdere stijging. (Insider?)
Re: DPRX
Dit is de reden v d stijging : http://www.prnewswire.com/news-releases ... 23725.html
Ik heb ze nog steeds en houd ze ook aan!
Ik heb ze nog steeds en houd ze ook aan!
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: DPRX
Heb ze zelf ook nog
"The man who begins to speculate in stocks with the intention of making a fortune usually goes broke, wheras the man who trades with a view of getting good interest on his money sometimes gets rich". - Charles Henry Dow
Re: DPRX
Hallo Insider,
Dank voor uw reactie! Momenteel stijgend
Dank voor uw reactie! Momenteel stijgend
Re: DPRX
Jpke normaal is dit nog maar het begin v d stijging : Lucci legt hier het fundament qua inkomsten voor de toekomst vast. Als het product werkt tenminste....DAT is het voornaamste gegeven in gans dit verhaal!
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: DPRX
Bestekes,
Iemand een verklaring voor de schommelingen van de laatste dagen?
Iemand een verklaring voor de schommelingen van de laatste dagen?
Re: DPRX
ik weet het ook niet ... winstnemingen ?? of .... investeerders die meer weten dan wij
Het lijkt zich wat te gaan herstellen : zit terug boven $15 ...
Het lijkt zich wat te gaan herstellen : zit terug boven $15 ...
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: DPRX
We are pleased to have SME designation, which allows us to benefit from financial incentives and support from the EMA as we aim to bring Locilex to the global pharmaceutical marketplace," said David P. Luci, President and Chief Executive Officer of Dipexium.
http://finance.yahoo.com/news/dipexium- ... 00914.html
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: DPRX
Top-line data from pivotal Phase 3 trials of Locilex in Mild Infections of Diabetic Foot Ulcers expected shortly
NEW YORK, Oct. 4, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq:
DPRX) ("Dipexium" or the "Company"), a late-stage pharmaceutical company focused on
the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel,
broad spectrum, topical antimicrobial peptide, today announced that it has been granted
Small and Medium Enterprise (SME) designation by the European Medicines Agency
(EMA). The Company recently completed its pivotal Phase 3 clinical trials (OneStep-1 and
OneStep-2) with Locilex in mild infections of diabetic foot ulcers in the U.S. under a
Special Protocol Assessment (SPA) agreement from FDA. Dipexium expects to have topline
data from these trials available for release shortly as its scientific advisory team is
finalizing the database, which currently remains blinded.
The SME designation was established by EMA to promote innovation and the
development of new medicinal products by smaller companies. Companies with SME
status are eligible to receive financial incentives as well as administrative and regulatory
support through national and regional level programs. These benefits include access to
dedicated EMA personnel during the clinical development process as well as reductions in
fees associated with regulatory procedures such as Scientific Advice, Marketing
Authorizations, and inspections.
"We are pleased to have SME designation, which allows us to benefit from financial
incentives and support from the EMA as we aim to bring Locilex to the global
pharmaceutical marketplace," said David P. Luci, President and Chief Executive Officer of
Dipexium."
With prior guidance from the EMA, the results from our clinical trials conducted in the
U.S. will form the basis for the planned Marketing Authorization Application to be
submitted shortly after filing our New Drug Application Amendment with the FDA,"
concluded Mr. Luci.
NEW YORK, Oct. 4, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq:
DPRX) ("Dipexium" or the "Company"), a late-stage pharmaceutical company focused on
the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel,
broad spectrum, topical antimicrobial peptide, today announced that it has been granted
Small and Medium Enterprise (SME) designation by the European Medicines Agency
(EMA). The Company recently completed its pivotal Phase 3 clinical trials (OneStep-1 and
OneStep-2) with Locilex in mild infections of diabetic foot ulcers in the U.S. under a
Special Protocol Assessment (SPA) agreement from FDA. Dipexium expects to have topline
data from these trials available for release shortly as its scientific advisory team is
finalizing the database, which currently remains blinded.
The SME designation was established by EMA to promote innovation and the
development of new medicinal products by smaller companies. Companies with SME
status are eligible to receive financial incentives as well as administrative and regulatory
support through national and regional level programs. These benefits include access to
dedicated EMA personnel during the clinical development process as well as reductions in
fees associated with regulatory procedures such as Scientific Advice, Marketing
Authorizations, and inspections.
"We are pleased to have SME designation, which allows us to benefit from financial
incentives and support from the EMA as we aim to bring Locilex to the global
pharmaceutical marketplace," said David P. Luci, President and Chief Executive Officer of
Dipexium."
With prior guidance from the EMA, the results from our clinical trials conducted in the
U.S. will form the basis for the planned Marketing Authorization Application to be
submitted shortly after filing our New Drug Application Amendment with the FDA,"
concluded Mr. Luci.
"The man who begins to speculate in stocks with the intention of making a fortune usually goes broke, wheras the man who trades with a view of getting good interest on his money sometimes gets rich". - Charles Henry Dow
Re: DPRX
Je was me één minuut voorinsider schreef:We are pleased to have SME designation, which allows us to benefit from financial incentives and support from the EMA as we aim to bring Locilex to the global pharmaceutical marketplace," said David P. Luci, President and Chief Executive Officer of Dipexium.
http://finance.yahoo.com/news/dipexium- ... 00914.html
"The man who begins to speculate in stocks with the intention of making a fortune usually goes broke, wheras the man who trades with a view of getting good interest on his money sometimes gets rich". - Charles Henry Dow
Re: DPRX
in de marge van de verdere ontwikkeling van antibiotica lijkt dit me een heel interessante ontdekking naar de toekomst toe : http://www.telegraph.co.uk/women/health ... gainst-th/
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: DPRX
ik heb de indruk dat de daling te wijten was aan een gekend fenomeen "'shaking out the weak hands" ... maar misschien ook niet ....
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: DPRX
Het zal wellicht wel aan mij liggen , maar ik begrijp de uitdrukking "'shaking out the weak hands" niet ?
Kan je even verduidelijken.
thx
Kan je even verduidelijken.
thx
Re: DPRX
het komt erop neer dat men de prijs laat dalen zodat "bange" traders hun aandelen ook gaan verkopen o.a. aan diegenen die het spelletje gestart zijn. Deze laatsten hebben dan wat ze willen natuurlijk : goedkope aandelen...
let wel : ik zeg niet dat het hier zo is hé ... ik denk dat gewoon ....
let wel : ik zeg niet dat het hier zo is hé ... ik denk dat gewoon ....
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: DPRX
Ik had nog een order stop loss staan die ik uit het oog verloren heb.
gevolg door de koersval gisteren automatisch verkocht aan 12.45USD.
Ik kan eigenlijk niet inschatten als ik nu blij moet zijn of niet?
gevolg door de koersval gisteren automatisch verkocht aan 12.45USD.
Ik kan eigenlijk niet inschatten als ik nu blij moet zijn of niet?